Cormorant Asset Management, LLC

revealed that they own 5% of AnaptysBio, Inc. (NASDAQ:ANAB) in a Schedule 13G disclosure that was filed with the SEC on Friday, October 20th. The investor owns 1,168,394 shares of the stock valued at approximately $75,560,040. The reporting parties listed on the disclosure included Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LLC and Bihua Chen. The disclosure is available through EDGAR at this link.

Several other hedge funds also recently made changes to their positions in the company. State Street Corp grew its stake in shares of AnaptysBio by 108.8% in the second quarter. State Street Corp now owns 74,833 shares of the biotechnology company’s stock worth $1,791,000 after acquiring an additional 38,996 shares during the period. DAFNA Capital Management LLC grew its stake in shares of AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 1,000 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of AnaptysBio in the second quarter worth approximately $277,000. Vanguard Group Inc. grew its position in AnaptysBio by 22.6% during the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock valued at $4,931,000 after buying an additional 37,932 shares during the period. Finally, Northern Trust Corp grew its position in AnaptysBio by 360.6% during the second quarter. Northern Trust Corp now owns 60,042 shares of the biotechnology company’s stock valued at $1,436,000 after buying an additional 47,005 shares during the period. Hedge funds and other institutional investors own 71.35% of the company’s stock.

Shares of AnaptysBio, Inc. (NASDAQ ANAB) traded down 3.10% during mid-day trading on Friday, reaching $64.67. 240,327 shares of the company traded hands. The firm’s market capitalization is $1.32 billion. The firm has a 50-day moving average price of $41.23 and a 200 day moving average price of $28.86. AnaptysBio, Inc. has a 52 week low of $15.17 and a 52 week high of $74.00.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The firm had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $3.45 million. On average, analysts anticipate that AnaptysBio, Inc. will post ($1.99) earnings per share for the current year.

In other AnaptysBio news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total value of $1,648,156.86. Following the completion of the transaction, the insider now owns 3,009,949 shares in the company, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. Insiders sold a total of 1,133,940 shares of company stock worth $24,223,316 in the last 90 days.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/20/cormorant-asset-management-llc-has-5-stake-in-anaptysbio-inc-anab.html.

Several brokerages recently issued reports on ANAB. Stifel Nicolaus restated a “buy” rating and set a $76.00 target price (up from $35.00) on shares of AnaptysBio in a research report on Friday, October 13th. Wedbush restated an “outperform” rating and set a $75.00 target price (up from $37.00) on shares of AnaptysBio in a research report on Friday, October 13th. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Robert W. Baird set a $69.00 target price on shares of AnaptysBio and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Royal Bank Of Canada boosted their target price on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. AnaptysBio has a consensus rating of “Buy” and an average price target of $71.71.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.